Alpha Cognition Inc 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-42403 Alpha Cognition Inc.(Exact Name of Registrant as Specified in its Charter) Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on whichregistered: Indicate by checkmark whether the registrant (1)filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany” and “emerging growth company” in Rule 12b-2 of the Exchange Act: Large Accelerated Filer☐Accelerated Filer☐Non-Accelerated Filer☒Smaller Reporting Company☒Emerging Growth Company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes☐No☒ Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practical date:21,777,868common shares, without par value, outstanding as of August 13, 2026. ALPHA COGNITION INC.FORM10-QFor the Quarter Ended June 30, 2026INDEX PagePART I – FINANCIAL INFORMATIONITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS1ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS19ITEM 3. – QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK31ITEM 4. CONTROLS AND PROCEDURES31PART II – OTHER INFORMATIONITEM 1. LEGAL PROCEEDINGS32ITEM 1A. RISK FACTORS32ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS32ITEM 3. DEFAULTS UPON SENIOR SECURITIES33ITEM 4. MINE SAFETY DISCLOSURE33ITEM 5. OTHER INFORMATION33ITEM 6. EXHIBITS33SIGNATURES34 PART I ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS. ALPHA COGNITION INC.CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS Cash and cash equivalents$ 41,384,287$ 66,046,789Restricted cash58,40058,400Accounts receivable, net5,474,9564,236,136Inventory6,394,8175,123,496Prepaid expenses and other current assets4,614,2223,545,451Total current assets57,926,68279,010,272Equipment, net374,692328,540Intangible assets, net6,218,509391,423Total assets$ 64,519,883$ 79,730,235 ALPHA COGNITION INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(UNAUDITED) For theThree Months EndedJune 30,For theSix Months EndedJune 30,2026202520262025 ALPHA COGNITION INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY(UNAUDITED) AccumulatedAdditionalOtherCommon StockPreferred StockPaid-InComprehensiveAccumulatedSharesAmount Shares Amount CapitalLossDeficitTotal ALPHA COGNITION INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY(UNAUDITED) ALPHA COGNITION INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED) NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 – NATURE OF OPERATIONS Alpha Cognition Inc. (“ACI” or the “Company”) is a commercial stage, biopharmaceutical company dedicated to developingtreatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s Disease, for which there are limited or notreatment options. The Company focuses on the commercial manufacturing and commercial sales of its ZUNVEYL oral tabletformulation, which was launched on March 19, 2025. The Company’s commercial program for ZUNVEYL is primarily focused on itslong-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing AChEItreatments, and franchising potential additional indications and new products. On November 12, 2024, the Company’s common stock commenced trading on the NASDAQ stock exchange under the symbol“ACOG”. The Company’s common stock traded on the Canadian Securities Exchange (“CSE”) under the symbol “ACOG” from May1, 2023 to December 17, 2024 on which date they were voluntarily delisted. NOTE 2 – REVISIONS TO P